HLB PharmaceuticalHLB제약
047920 · KOSDAQ · ₩047920 · HLB제약
₩9,890▲ ₩160 (1.64%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩206B | ₩137B | ₩136B | ₩107B | ₩63B |
| Cost of sales | ₩99B | ₩51B | ₩53B | ₩43B | ₩27B |
| Gross profit | ₩107B | ₩87B | ₩83B | ₩64B | ₩35B |
| Operating income | ₩1.1B | ₩1.5B | −₩20B | −₩6.4B | ₩486M |
| Net income | ₩4.6B | ₩2B | −₩19B | −₩12B | −₩13B |
| Net income to shareholders | ₩4.6B | ₩2B | −₩19B | −₩12B | −₩13B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩171B | ₩158B | ₩141B | ₩142B | ₩128B |
| Current assets | ₩77B | ₩63B | ₩72B | ₩60B | ₩51B |
| Cash and equivalents | ₩7.6B | ₩10B | ₩4.8B | ₩9.7B | ₩6.6B |
| Total liabilities | ₩46B | ₩42B | ₩53B | ₩56B | ₩49B |
| Current liabilities | ₩40B | ₩39B | ₩49B | ₩53B | ₩46B |
| Borrowings | ₩15B | ₩15B | ₩22B | ₩24B | ₩30B |
| Total equity | ₩125B | ₩116B | ₩88B | ₩86B | ₩78B |
| Shareholders' equity | ₩125B | ₩116B | ₩88B | ₩86B | ₩78B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩569M | ₩6.8B | −₩18B | −₩2.8B | −₩1.3B |
| Capital spending | ₩7.2B | ₩2.8B | ₩2.7B | ₩2.7B | ₩49B |
| Free cash flow | −₩6.6B | ₩4B | −₩21B | −₩5.5B | −₩51B |
Consolidated where available. Amounts in won.
Also known as: HLB Pharmaceutical / HLB제약 / 047920 / KRX:047920
Source: KRX statistical information